Statement: Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is not a requirement for the secondary trial.
Primary_evidence: Inclusion Criteria:   Histologically confirmed stage I-III colorectal or breast cancer   Undergone curative-intent complete surgical resection and completed all adjuvant therapy (if indicated) at least 2 months prior to enrollment   Note: Breast cancer subjects on hormonal therapy or trastuzumab only therapy and colorectal cancer subjects on adjunctive therapies not considered cytotoxic chemotherapy (including those participating in CALGB 80702 receiving only celecoxib/placebo) are eligible.   Participants will be allowed to receive concomitant adjuvant endocrine therapy for breast cancer; however, all endocrine agents must be initiated at least 1 month prior to enrollment in the study and continued throughout the duration of study participation.   Less than 120 minutes of exercise per week   Approval by oncologist or surgeon   English speaking and able to read English   No planned surgery anticipated in the 3 month intervention period   At least one month from any major surgery to start of intervention including colostomy reversal Exclusion Criteria:   Concurrent other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer or in-situ cervical cancer)   Metastatic disease   Scheduled to receive any form of further adjuvant cancer therapy   Currently on medication for diabetes treatment   Pregnant or breast-feeding   Any condition associated with increased risk of metformin-associated lactic acidosis (prior renal failure or liver failure, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)   Known hypersensitivity or intolerance to metformin
Secondary_evidence: Inclusion Criteria:   The patient has provided written informed consent with HIPAA authorization before participating in the study, as has his/her responsible caregiver, if applicable.   The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.   The patient is at least 18 years of age at the time of consent.   The patient has an ECOG performance status of Grade 0 - 2 [8].   The patient has a clinical negative node status at the time of study entry.   If of child bearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.   The patient is currently not participating in another investigational drug study.   Melanoma Patients   The patient has a diagnosis of primary melanoma.   Breast Cancer Patients   The patient has a diagnosis of primary breast cancer.   Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan. Exclusion Criteria:   The patient is pregnant or lactating;   The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0);   The patient has a known hypersensitivity to Lymphazurin or Patent Bleu V.   Melanoma Patients   The patient has a tumor with a Breslow depth less than 0.75mm.;   Patients that have had preoperative chemotherapy, immunotherapy or radiation therapy;   Patients diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin;   Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma;   Patients who have undergone a wide excision for their primary melanoma (>1 cm in dimension) or complex reconstruction (rotation, free flap or skin graft of any type).   Breast Cancer Patients   The patient has bilateral primary breast cancers or multiple tumors within their breast;   Patients that have had prior surgical procedures such as breast implants, reduction mammoplasty or axillary surgery;   Patients scheduled for bilateral mastectomy for any reason;   Patients that have had preoperative radiation therapy to the affected breast or axilla